In the first-in human Phase 1 study of NKG2D-CAR T cells in patients with AML and multiple myeloma, no safety or feasibility concerns were raised, but a clinical efficacy signal was not seen (40). This evidence concerns the gene KLRK1 and AL amyloidosis.